Lupin Launches Generic Motegrity for CIC Treatment

  Published 1 year ago

Lupin’s generic Prucalopride treats CIC in adults bioequivalent to Motegrity, made in Goa, India. IQVIA data shows $184M annual US sales for Prucalopride (Motegrity reference drug) in April 2025. Lupin, a Mumbai based global leader, distributes products in 100+ markets, specializing in diverse pharmaceuticals.

  • Lupin’s generic Prucalopride treats CIC in adults bioequivalent to Motegrity, made in Goa, India.
  • IQVIA data shows $184M annual US sales for Prucalopride (Motegrity reference drug) in April 2025.
  • Lupin, a Mumbai, based global leader, distributes products in 100+ markets, specializing in diverse pharmaceuticals.

You might like these

RBI Reports Weekly Currency and Reserve Money Trends

Nykaa Q4 FY25: Strong Growth & Profit Surge

Sterlite Tech Stock Surges 35% in 2 Days

Ircon Q1 Profit, Revenue Decline

IndusInd Bank, DPIIT Ink Deal to Support Startups

Netflix: Live Events & Analyst Downgrade

TVS iQube Launches New Electric Scooter Variant

News that matters the most ⚡